Table 2.
Small molecule BACE1 inhibitors in clinical trials
| Company | Drug | Phase |
|---|---|---|
| AstraZeneca/Lilly | AZD3293 | Phase 2/3 |
| CoMentis | CTS-21166 | Phase 1 |
| Eisai/Biogen Idec | E2609 | Phase 2 |
| High Point | HPP854 | Phase 1 |
| Janssen/Shionogi | - - - - - - | Phase 1 |
| Lilly | LY2886721 | Phase 2* |
| Merck | MK-8931 | Phase 2/3 |
| Novartis | - - - - - - | Phase 1 |
| Pfizer | PF-05297909 | Phase 1 |
| Roche | RG7129 | Phase 1** |
| Takeda | TAK-070 | Phase 1 |
| Vitae/Boehringer Ingelheim | VTP-37948 | Phase 1 |
*Terminated due to abnormal liver biochemistry.
**Removed from pipeline.